adalimumab-aaty (Yuflyma) vs adalimumab-adbm (Cyltezo)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
adalimumab-aaty (Yuflyma)
Marketed by Celltrion
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
NCT02871635 · Phase 3 · completed
This was a randomized, double-blind trial against the reference adalimumab product, with a validated Crohn's disease activity score as the primary endpoint. Clinical response at week 4 was similar in both groups (risk ratio 0.945, 90% CI 0.870 to 1.028), within the prespecified non-inferiority margin, and 147 people were randomized against a planned 130.
Hanauer et al. (Lancet Gastroenterol Hepatol, 2021; PMID 34388360) report different figures for this outcome, clinical response in 61 of 68 patients (90%) with BI 695501 and 68 of 72 (94%) with the reference product, because the registry figures are model-based least-squares means.
Reported efficacy
Percentage of Patients With a Clinical Response (CDAI Decrease of ≥70 Compared With Baseline) at Week 4: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol). (met)
Result source: NCT02871635
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-aaty (Yuflyma) | adalimumab-adbm (Cyltezo) |
|---|---|---|
| Clinical remission (induction) | —Not reported | —Not reported |
| Endoscopic response (induction) | —Not reported | —Not reported |
| Clinical remission (maintenance) | —Not reported | 68.6% vs 76.2%vs Humira EUNCT02871635 |
| Endoscopic response (maintenance) | —Not reported | —Not reported |
Clinical remission (induction)
- adalimumab-aaty (Yuflyma)
- —Not reported
- adalimumab-adbm (Cyltezo)
- —Not reported
Endoscopic response (induction)
- adalimumab-aaty (Yuflyma)
- —Not reported
- adalimumab-adbm (Cyltezo)
- —Not reported
Clinical remission (maintenance)
- adalimumab-aaty (Yuflyma)
- —Not reported
- adalimumab-adbm (Cyltezo)
- 68.6% vs 76.2%vs Humira EUNCT02871635
Endoscopic response (maintenance)
- adalimumab-aaty (Yuflyma)
- —Not reported
- adalimumab-adbm (Cyltezo)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
adalimumab-aaty (Yuflyma): no structured comparison results are available for Crohn's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab-aaty (Yuflyma): 0 of 4 rows · adalimumab-adbm (Cyltezo): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab-adbm (Cyltezo) |
|---|---|
| Dropout rate | 25%BI 695501 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 show 2 more results—BI 695501 (Baseline - Week 24 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 —BI 695501 (Week 24 - Week 46 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 |
| Discontinued due to AEs | 5.6%BI 695501 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 show 2 more results—BI 695501 (Baseline - Week 24 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 —BI 695501 (Week 24 - Week 46 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 |
| Serious AEs | —BI 695501 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 show 2 more results8.3%BI 695501 (Baseline - Week 24 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 2.8%BI 695501 (Week 24 - Week 46 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 |
| Most frequent reported AEs | arthralgia 8.3% respiratory tract infection 6.9% crohn's disease 5.6% NCT02871635 · Phase 3 · Crohn's Disease · phase 3 show 1 more resultnasopharyngitis 6.9% weight increased 4.2% arthralgia 2.8% NCT02871635 · Phase 3 · Crohn's Disease · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab-adbm (Cyltezo)
show 1 more result
Psoriasis
Shared mechanism: TNF-alpha · full Psoriasis pipeline
adalimumab-aaty (Yuflyma)
Marketed by Celltrion
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
NCT03210259 · Phase 3 · completed
After a 14-week Humira run-in, 238 patients were randomized to switch between Cyltezo and Humira or continue Humira in a double-blind active-controlled period. Both primary pharmacokinetic comparisons met the prespecified equivalence range, but these were drug-level measures rather than direct clinical psoriasis outcomes, so the evidence is moderate. Its registered primary outcomes are pharmacokinetic measures with no comparison, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-aaty (Yuflyma) | adalimumab-adbm (Cyltezo) |
|---|---|---|
| PASI 75 | —Not posted · NCT05495568 | —Not reported |
| PASI 90 | —Not posted · NCT05495568 | —Not reported |
| PASI 100 | —Not posted · NCT05495568 | —Not reported |
| sPGA 0/1 | —Not posted · NCT05495568 | —Not reported |
| DLQI, change | —Not posted · NCT05495568 | —Not reported |
PASI 75
- adalimumab-aaty (Yuflyma)
- —Not posted · NCT05495568
- adalimumab-adbm (Cyltezo)
- —Not reported
PASI 90
- adalimumab-aaty (Yuflyma)
- —Not posted · NCT05495568
- adalimumab-adbm (Cyltezo)
- —Not reported
PASI 100
- adalimumab-aaty (Yuflyma)
- —Not posted · NCT05495568
- adalimumab-adbm (Cyltezo)
- —Not reported
sPGA 0/1
- adalimumab-aaty (Yuflyma)
- —Not posted · NCT05495568
- adalimumab-adbm (Cyltezo)
- —Not reported
DLQI, change
- adalimumab-aaty (Yuflyma)
- —Not posted · NCT05495568
- adalimumab-adbm (Cyltezo)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
adalimumab-aaty (Yuflyma): no structured comparison results are available for Psoriasis.
adalimumab-adbm (Cyltezo): registry results are on file for Psoriasis, but their comparison mappings are not yet available.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-aaty (Yuflyma)
Marketed by Celltrion
NCT03789292 · Phase 3 · completed
This randomized, double-blind Phase 3 equivalence trial compared CT-P17 (Yuflyma) with EU-approved Humira in 648 adults with active rheumatoid arthritis. The primary endpoint was ACR20 response at week 24, and equivalence required the confidence interval of the difference to fall inside predefined margins. ACR20 response was 82.7% in both groups; the 95% CI (-5.94 to 5.94) and the 90% CI (-4.98 to 4.98) were inside the margins, so equivalence was shown and the primary endpoint was met. Source: the peer-reviewed trial report (Kay 2021).
Reported efficacy
American College of Rheumatology(ACR)20 Response Rate at Week 24.: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther). (met)
Result source: NCT03789292
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
NCT02137226 · Phase 3 · completed
The 645-participant study was randomized, double-blind, and active-controlled against US-licensed Humira, with ACR20 response as the primary clinical endpoint. The prespecified equivalence margins were met at both Week 12 and Week 24, so the comparison supports equivalent clinical response between BI 695501 and Humira.
No aligned efficacy figure on record for this race.
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-aaty (Yuflyma) | adalimumab-adbm (Cyltezo) |
|---|---|---|
| ACR20 | 82.7% vs 82.7%vs HumiraNCT03789292 | —Not reported |
| ACR50 | —Not reported | —Not reported |
| ACR70 | —Not reported | —Not reported |
| DAS28-CRP remission | —Not reported | —Not reported |
| HAQ-DI, change | —Not reported | —Not reported |
| Modified Sharp score, change | —Not reported | —Not reported |
ACR20
- adalimumab-aaty (Yuflyma)
- 82.7% vs 82.7%vs HumiraNCT03789292
- adalimumab-adbm (Cyltezo)
- —Not reported
ACR50
- adalimumab-aaty (Yuflyma)
- —Not reported
- adalimumab-adbm (Cyltezo)
- —Not reported
ACR70
- adalimumab-aaty (Yuflyma)
- —Not reported
- adalimumab-adbm (Cyltezo)
- —Not reported
DAS28-CRP remission
- adalimumab-aaty (Yuflyma)
- —Not reported
- adalimumab-adbm (Cyltezo)
- —Not reported
HAQ-DI, change
- adalimumab-aaty (Yuflyma)
- —Not reported
- adalimumab-adbm (Cyltezo)
- —Not reported
Modified Sharp score, change
- adalimumab-aaty (Yuflyma)
- —Not reported
- adalimumab-adbm (Cyltezo)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
adalimumab-adbm (Cyltezo): registry results are on file for Rheumatoid Arthritis, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab-aaty (Yuflyma): 4 of 4 rows · adalimumab-adbm (Cyltezo): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab-aaty (Yuflyma) |
|---|---|
| Dropout rate | 6.5%CT-P17 Subcutaneous(SC) (Adalimuma NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 4 more results—Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 1: CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: CT-P17 Maintenance NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 |
| Discontinued due to AEs | 2.2%CT-P17 Subcutaneous(SC) (Adalimuma NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 4 more results—Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 1: CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: CT-P17 Maintenance NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 |
| Serious AEs | —CT-P17 Subcutaneous(SC) (Adalimuma NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 4 more results—Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 3.7%Treatment 1: CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 2%Treatment 2: CT-P17 Maintenance NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 3.3%Treatment 2: Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 |
| Most frequent reported AEs | upper respiratory tract infection 5.6% nasopharyngitis 5.2% injection site reaction 4.9% NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 show 2 more resultsneutropenia 5% upper respiratory tract infection 3.3% urinary tract infection 3% NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 neutropenia 5.3% alanine aminotransferase increased 4.6% leukopenia 4.6% NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab-aaty (Yuflyma)
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-aaty (Yuflyma)'s landscape · adalimumab-adbm (Cyltezo)'s landscape